Kelly Michael 4
4 · ARS Pharmaceuticals, Inc. · Filed Jun 26, 2026
Research Summary
AI-generated summary of this filing
ARS Pharmaceuticals (SPRY) Director Kelly Michael Receives 30,000-Share Award
What Happened
Kelly Michael, a director of ARS Pharmaceuticals (SPRY), was granted a derivative award of 30,000 shares on 2026-06-24. The reported acquisition price is $0.00 (i.e., no cash paid). This was a grant/award (Form 4 code A), not an open-market purchase or sale—commonly a retention or compensation award rather than a direct bullish purchase.
Key Details
- Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (timely filing).
- Security: 30,000 derivative shares granted at $0.00 per share (total reported value $0).
- Shares owned after transaction: not specified in the provided filing.
- Footnote: The award vests in full on the earlier of June 24, 2027 or the date of the issuer’s 2027 annual meeting of stockholders.
- Transaction code: A (grant/award). No 10b5-1 plan, tax-withholding, or immediate sale indicated in the disclosed items.
Context
This is a derivative grant (likely restricted stock units or a similar award) that will vest over time; no exercise or immediate sale occurred. Such awards are typically compensation/retention tools for insiders and do not by themselves indicate immediate trading sentiment. The filing appears timely under Form 4 rules.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-24+30,000→ 30,000 totalExercise: $10.54Exp: 2036-06-23→ Common Stock (30,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.